This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
02/09/16 - 9:46:37 AM ET (BATS BZX Real-time Price)
Div Yield: --
HALO Day's Range
HALO 52 Week Range
HALO Business Summary
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes.View HALO
Halozyme Therapeutics Inc - HALO - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Halozyme Therapeutics Inc as a
Sell with a ratings score of D.
Report Snippet: We rate HALOZYME THERAPEUTICS INC (HALO) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally high debt management risk, weak operating cash flow and generally disappointing historical performance in the stock itself.